Announcements Trials
Browse Landscape

Phase

Phase 2 5Phase 1/2 2

Status

Recruiting 56Active not recruiting 32Not yet recruiting 12Completed 11Terminated 7Withdrawn 3Unknown 2Enrolling by invitation 2Approved for marketing 1

Sponsor Class

INDUSTRY 5OTHER 1NIH 1

Study Type

Interventional 7

Sponsor

Cancer Type

Breast 3Genitourinary 2Tumor-Agnostic 1Thoracic 1Gynecologic 1

Conditions

Triple Negative Breast Neoplasms 3Urinary Bladder Neoplasms 1Recurrence 1Ovarian Neoplasms 1Neoplasms 1Carcinoma, Transitional Cell 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Cyclophosphamide 391Carboplatin 344Gemcitabine 332pembrolizumab 331Cisplatin 328Paclitaxel 298Radiotherapy 297Docetaxel 287Bevacizumab 253Rituximab 234Capecitabine 224Nivolumab 222Dexamethasone 206Fluorouracil 190fludarabine 178Oxaliplatin 177Pemetrexed 153Doxorubicin 153Irinotecan 148Leucovorin 144Etoposide 144Cytarabine 134Cetuximab 130fludarabine phosphate 129Bortezomib 129Lenalidomide 126Filgrastim 120Erlotinib Hydrochloride 120Temozolomide 113Radiosurgery 113

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

7 trials
RecentStart dateEnrollment
Terminated × sacituzumab govitecan × Clear all
NCT03337698 2026-05-12

Morpheus Lung

Hoffmann-La Roche

Phase 1/2 Terminated
314 enrolled 31 charts
Thoracic

Carcinoma, Non-Small-Cell Lung

NCT05581589 2026-04-27

Sacituzumab Govitecan Before Radical Cystectomy for the Treatment of Non-Urothelial Muscle Invasive Bladder Cancer

University of Washington

Phase 2 Terminated
4 enrolled 13 charts
Genitourinary

Urinary Bladder Neoplasms

NCT06865677 2026-01-21

Sacituzumab Govitecan for Relapsed Ovarian, Endometrial, and Cervical Carcinomas

National Institutes of Health Clinical Center (CC)

Phase 2 Terminated
2 enrolled 7 charts

Recurrence

NCT04958785 2025-11-04

ELEVATE TNBC

Gilead Sciences

Phase 2 Terminated
92 enrolled 27 charts
Breast

Triple Negative Breast Neoplasms

NCT05113966 2025-01-29

Trilaciclib in Patients Receiving Sacituzumab Govitecan-hziy for Triple Negative Breast Cancer

G1 Therapeutics, Inc.

Phase 2 Terminated
30 enrolled 16 charts
Breast

Triple Negative Breast Neoplasms

NCT05097599 2025-01-08

StrataPATH

Strata Oncology

Phase 2 Terminated
11 enrolled
Tumor-Agnostic

Neoplasms

NCT03992131 2024-01-16

A Study to Evaluate Rucaparib in Combination With Other Anticancer Agents in Participants With a Solid Tumor (SEASTAR)

pharmaand GmbH

Phase 1/2 Terminated
25 enrolled 11 charts
BreastGenitourinaryGynecologic

Carcinoma, Transitional Cell, Ovarian Neoplasms, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡